Piper Sandler Reiterates Overweight Rating on Sutro Biopharma (STRO)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
TD Cowen Reiterates Buy Rating on Sutro Biopharma (STRO)
September 16, 2024 9:11 AM EDTTD Cowen analyst Tara Bancroft reiterated a Buy rating on Sutro Biopharma (NASDAQ: STRO).
The analyst commented, "Luvelta+bev's 35% ORR in an unselected population and multiple doses is impressive on its own given that Elahere+bev had a 44% ORR in higher... More
